Табакьян Е. А., Тоневицкий А. Г., Атауллаханова Д. М., Заруба А. Ю., Кухарчук В. В. Определение аутоантител против β1-адренорецептора и влияние их удаления на сократительную функцию миокарда левого желудочка у больных дилатационной кардиомиопатией. Кардиоваскулярная терапия и профилактика. 2007;6(3):25-32.
1. Grogan M, Redfoeld MM, Bailey KR, et al. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. JACC 1995; 26(1): 80-4.
2. Erdmann E. Tne management of the heart failure – an overview. Basic Res Cardiol 2000; 95: 13-7.
3. Freedman NJ, Lefkowitz RJ. Anti-β1-adrenergic receptor antibod- ies and heart failure: causation, not just correlation. J Clin Invest 2004; 113: 1379-82.
4. Шумаков В.И., Рулева Н.Ю., Коробов Н.В. и др. Разработка аналитического метода на основе иммуноферментного анализа для определения аутоантител к β1-адренорецепторам в сыворотке крови больных с дилатационной кардиомиопатией. Вест трансплант искусст орг 1999; 34-41.
5. Caforio AL, Goldman JH, Baig MK, et al. Cardiac autoantibodies in dilated cardiomyophathy become unedetectable with disease progression. Heart 1997; 77: 62-7.
6. Tomaszewski M, Brain NJ, Charchar FJ, et al. Essential Hypertension and β2-Adrenergic Receptor Gene. Hypertension 2002; 40: 286-91.
7. Lohse MJ, Engelhardt S, Eschenhagen, T. What ist he role of β-adrenergic signaling in heart failure? Circ Res 2003; 93: 896-906.
8. Lader AS, Xiao YF, Ishikawa Y, et al. Cardiac Gsα overexpression enhances L-type calcium channels through an adenylyl cyclase independent pathway. Proc Natl Acad Sci USA 1998; 95: 9669-74.
9. Matsui S, Fu ML, Hoebeke JJ. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopatic changes in immunized rabbits. Mol Cell Cardiol 1977; 29: 641-55.
10. Jahns R, Вoivin V, Hein L, et al. Direct evidence for a β1-adrenergic receptor–directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004; 113: 1419-29.
11. Knebel F, Bohm M, Staudt A, et al. Reduction of morbidity by immunoadsorbtion therapy in patients with dilated cardiomyopathy. Int J Cardiol 2004; 97(3): 517-20.
12. Felix SB, Staudt A, Dorffel WD, et al. Hemodynamic Effects of Immunoadsorbtion and Subsequent Immunoglobulin Substitution in Dilated Cardiomyopathy. Three-Month from a Randomized Study. JACC 2000; 35(6): 1590-8.
13. Wisdom G.V. Peptide Antigens. Oxford University Press Inc. Oxford New York Tokyo 1994; 252.
14. Fraser CM. Site-directed mutagenesis of β-adrenergic receptors. J Biol Chem 1989; 264: 9266-70.
15. Strader CD, Candelore MR, Hill WS, et al. Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J Biol Chem 1989; 264: 13572-80.
16. Tota MR, Candelore MR, Dixon RAF, Strader CD. Biophysical and genetic analysis of the ligand binding site of the beta-adrenoceptor. Trends Pharmacol Sci 1991; 12: 4-6.
17. Naparstek Y, Plotz PH. The role of autoantibodies in autoimmune disease. Annu Rev Immunol 1993; 11: 79-104.
18. Kaplan D, Ferrari I, Bergami PL, et al. Antibodies to ribosomal P proteins of Tripanosoma cruzi in Chagas disease possess functional autoreactivity with heart tissue and differ from anti-P autoantibodies in lupus. Proc Natl Acad Sci USA 1997; 94: 10301-6.